Stock analysts at StockNews.com began coverage on shares of IRIDEX (NASDAQ:IRIX – Get Free Report) in a research report issued on Sunday. The firm set a “hold” rating on the medical equipment provider’s stock.
IRIDEX Price Performance
Shares of IRIDEX stock opened at $1.89 on Friday. The company’s fifty day moving average price is $1.97 and its two-hundred day moving average price is $2.37. The firm has a market capitalization of $30.72 million, a PE ratio of -2.82 and a beta of 0.78. IRIDEX has a 52-week low of $1.63 and a 52-week high of $3.65.
IRIDEX (NASDAQ:IRIX – Get Free Report) last posted its quarterly earnings results on Thursday, August 8th. The medical equipment provider reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.04). The business had revenue of $12.63 million during the quarter, compared to analyst estimates of $12.80 million. IRIDEX had a negative return on equity of 134.37% and a negative net margin of 21.84%. During the same period last year, the company earned ($0.17) EPS. Analysts predict that IRIDEX will post -0.52 earnings per share for the current fiscal year.
Institutional Trading of IRIDEX
About IRIDEX
IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments.
Read More
- Five stocks we like better than IRIDEX
- What Are Dividend Challengers?
- Take Advantage of Village Farms Stock as Cannabis Market Evolves
- 3 Best Fintech Stocks for a Portfolio Boost
- MarketBeat Week in Review – 9/16 – 9/20
- How to Invest in Biotech Stocks
- Don’t Miss These 3 Retail Stocks for Fall Gains
Receive News & Ratings for IRIDEX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IRIDEX and related companies with MarketBeat.com's FREE daily email newsletter.